BRNS vs CUBE · rev $15.0M vs P/E 25, rev $1.07B
Barinthus Biotherapeutics plc (BRNS) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Barinthus Biotherapeutics plc (BRNS) is a biotechnology company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported BRNS revenue for 2024-12-31 was $15.0M. Net income was -$61.2M. Revenue was up 1766.5% from 2023-12-31 to 2024-12-31. BRNS currently screens at market cap $38.2M.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
BRNS currently screens at market cap $38.2M. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the BRNS and CUBE stock pages for the full models.
Not investment advice.